679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The exploration of GLP-1 receptor agonists for weight loss in end-stage heart failure patients awaiting heart transplantation carries profound implications for clinical practice and patient access to life-saving proce…
Liraglutide's efficacy for glycemic control was compared against metformin monotherapy and metformin/glimepiride combination in 1091 Type 2 Diabetes patients.
Should this trial demonstrate that Insulin Degludec/Liraglutide (IDegLira) significantly improves Time in Range while simultaneously reducing markers of inflammation and endothelial dysfunction compared to a tradition…
Clinical trial NCT01451905 aims to characterize GLP-1 receptors in psoriatic skin and evaluate liraglutide for reducing psoriasis severity.
A completed observational study (NCT07374445) explored optimal liraglutide timing for patients remaining obese six months post-metabolic surgery.
For patients with severe insulin resistance in Type 2 Diabetes, optimizing glycemic control without excessive insulin burden is a critical challenge. High insulin doses often lead to weight gain and hypoglycemia, limi…
A higher-dose oral semaglutide could significantly impact obesity and overweight management by offering a potent, non-injectable alternative to existing therapies. Oral semaglutide 25 mg could provide enhanced conveni…
This trial directly confronts a significant challenge in GLP-1 therapy: mitigating the loss of lean muscle and bone mass during substantial weight reduction. If successful, the findings could establish a new, integrat…
This completed Phase II study for BI 456906 is a crucial step in developing new treatments for Type 2 Diabetes Mellitus and obesity. If positive, the findings could identify optimal dosing strategies for a novel compo…
If successful, this trial could establish semaglutide as a crucial adjunct therapy for individuals with Double Diabetes, potentially improving glycemic control beyond insulin alone and reducing overall insulin require…
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor …
Clarifying the link between semaglutide and NAION is critical for patient counseling and prescribing practices. If a significant association is confirmed, it could lead to updated guidelines for monitoring ocular heal…
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
This narrative review highlights the critical need for further research into the effects of GLP-1 agonists on bone health and orthopedic surgery outcomes. Clinicians should be aware of the limited current evidence reg…
This study introduces a powerful SPRM methodology for characterizing peptide-receptor interactions directly on live cells, offering a significant advancement over traditional methods. This label-free, real-time approa…
Liraglutide significantly upregulated GLP1R expression and activated cAMP/PKA signaling, inducing apoptosis and cell cycle arrest in MCF7 breast and PC-3 prostate cancer cells.
This case report underscores that personalized treatment strategies are crucial for managing EVAF in PLWH. For peptide users and clinicians, it reinforces that Tesamorelin and GLP-1R agonists are not interchangeable b…
Semaglutide offers a viable pathway for severely obese ESHF patients to become eligible for life-saving heart transplantation, potentially expanding access to this critical procedure. For clinicians, this suggests int…
This research offers a crucial shift in the narrative around GLP-1RA discontinuation, suggesting that weight regain is not an inevitable outcome for all patients. For individuals considering or undergoing GLP-1RA ther…
This Phase 3 trial represents a crucial step in exploring Liraglutide as an adjunctive therapy for Type 1 Diabetes, a population with significant unmet needs beyond insulin. If the study's hypotheses were confirmed, i…
This foundational dataset provides an unprecedented tool for understanding diabetic microvascular disease at a systemic level, moving beyond organ-specific views. For researchers and clinicians, it offers a quantitati…
If GLP-1R agonists are found to significantly reduce Lipoprotein(a) (Lp(a)) levels, it would represent a substantial advancement in managing cardiovascular risk for Type 2 Diabetes patients. This finding would add a n…
Effective strategies for weight loss maintenance are crucial, as regain is a major challenge in obesity management. This trial's design, focusing on subjects who already achieved initial weight loss through diet, dire…
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
Understanding the intricate link between gut microbiota composition and semaglutide responsiveness could usher in a new era of personalized obesity treatment. If specific microbial profiles are found to predict who wi…
If this trial demonstrates that Semaglutide can effectively prevent or mitigate metabolic deterioration in patients on antipsychotics, it would represent a significant clinical breakthrough. Schizophrenia patients oft…
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
This research suggests a novel therapeutic strategy for hypertension and hyperaldosteronism by combining a GLP-1R agonist with a PDE4 inhibitor. Combining liraglutide with roflumilast could offer enhanced cardiovascul…
Comprehensive understanding of GLP-1RA reproductive safety is paramount for women of reproductive age managing obesity or type 2 diabetes. This review underscores the necessity for robust research to establish clear g…
This finding is highly significant for individuals undergoing GLP-1 receptor agonist therapy, as it addresses a major concern: muscle loss. Combining GLP-1RAs with 15-PGDH inhibitors could preserve muscle mass and imp…
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. Fo…
This Phase 2 study is crucial for understanding the potential of liraglutide (a GLP-1 receptor agonist) as a combination therapy for Type 2 Diabetes. The findings, once fully published, could highlight a more effectiv…
This study holds significant promise for offering a powerful, non-surgical alternative to bariatric surgery for individuals with Type 2 Diabetes and Obesity, particularly within the veteran population. If successful, …
Optimizing treatment strategies for patients with Type 2 Diabetes and poor glycemic control is a critical unmet medical need, as uncontrolled blood sugar significantly increases the risk of severe complications. This …
This study is a methodological investigation designed to assess the concordance between real-world data analyses and the original SOUL Diabetes Trial results. As this record describes the study design and objectives r…
Understanding these pharmacokinetic interactions is critical for the safe and effective use of the semaglutide and NNC0480-0389 combination, especially for patients who may also be taking oral contraceptives or pain r…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
Understanding the interplay between GLP-1 RA therapy and cardiac biomarkers like NT-proBNP and hs-cTnT is crucial for refining cardiovascular risk stratification in Type 2 Diabetes. This research could help identify p…
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in …
This network meta-analysis provides a robust and comprehensive safety profile for oral Orforglipron, confirming its dose-dependent gastrointestinal side effects, which are common with GLP-1 RAs. The findings are cruci…
This case report highlights a critical, albeit rare, adverse event associated with rapid weight loss induced by GLP-1 receptor agonists in patients with cardiac implantable electronic devices (CIEDs). The finding sugg…
The development of GZR18 represents a significant step towards addressing the unmet need for more convenient and effective long-term weight management solutions. The potential for a less frequent dosing regimen (every…
This study provides compelling economic evidence that semaglutide 2.4 mg is a highly cost-effective treatment option for obese patients with MASH in Italy. These findings are crucial for health policy makers and payer…
This real-world evidence strongly supports the significant benefits of GLP-1 RAs not only for metabolic control but also for dramatically improving the daily lives of patients with type 2 diabetes and obesity. The obs…
This post hoc analysis provides crucial insights, suggesting that semaglutide's cardiovascular protective effects are robust and extend beyond its weight-reducing capabilities. This finding reinforces the drug's value…
These findings are highly significant as they suggest tirzepatide offers superior kidney protection compared to dulaglagutide, a widely used GLP-1 agonist, in patients with Type 2 Diabetes. Given that chronic kidney d…
Understanding GLP-1's direct vascular effects could significantly expand its therapeutic potential beyond mere glucose control, offering new avenues for patient care. If GLP-1 or its analogues demonstrate independent …
This summary underscores that semaglutide offers more than just weight reduction; it significantly enhances the quality of life for people living with obesity. Recognizing these broader benefits is crucial for healthc…
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…